This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Fenoldopam and Acute Renal Failure (FENO HSR)

This study has been completed.
Information provided by (Responsible Party):
Giovanni Landoni, Università Vita-Salute San Raffaele Identifier:
First received: February 12, 2008
Last updated: October 13, 2015
Last verified: October 2015
February 12, 2008
October 13, 2015
February 2008
June 2013   (Final data collection date for primary outcome measure)
Number of patients requiring Renal Replacement Therapy [ Time Frame: participants will be followed for the duration of intensive care unit stay, an expected average of one week ]
Renal Replacement Therapy [ Time Frame: Intensive Care Unit Stay ]
Complete list of historical versions of study NCT00621790 on Archive Site
Number of dead patients. [ Time Frame: Participants will be followed for 1 year. ]
Mortality [ Time Frame: INtensive Care Unit, Hospital, 30 days, 1 year ]
Not Provided
Not Provided
Fenoldopam and Acute Renal Failure
Efficacy of Fenoldopam in Reducing the Need for Renal Replacement Therapy After Cardiac Surgery. A Randomized Controlled Study.

Patients undergoing cardiac surgery could develop postoperative acute renal failure requiring renal replacement therapy.

Fenoldopam, already used for patients with hypertensive emergencies, could improve renal function in critically ill patients with or at risk for acute renal failure.

Not Provided
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Acute Renal Failure
  • Drug: fenoldopam
    fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min)for up to 4 days
    Other Name: corlopam
  • Drug: placebo
  • Experimental: Fenoldopam
    Fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min) for up to 4 days
    Intervention: Drug: fenoldopam
  • Placebo Comparator: Placebo
    Placebo (normosaline), continuous perfusion
    Intervention: Drug: placebo
Bove T, Zangrillo A, Guarracino F, Alvaro G, Persi B, Maglioni E, Galdieri N, Comis M, Caramelli F, Pasero DC, Pala G, Renzini M, Conte M, Paternoster G, Martinez B, Pinelli F, Frontini M, Zucchetti MC, Pappalardo F, Amantea B, Camata A, Pisano A, Verdecchia C, Dal Checco E, Cariello C, Faita L, Baldassarri R, Scandroglio AM, Saleh O, Lembo R, Calabrò MG, Bellomo R, Landoni G. Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. JAMA. 2014 Dec 3;312(21):2244-53. doi: 10.1001/jama.2014.13573.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
June 2013
June 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • adult patients
  • who underwent cardiac surgery
  • have Risk of Acute Renal Failure (R of RIFLE score)

Exclusion Criteria:

  • glaucoma
  • already on renal replacement therapy
  • study drug in the past 30 days
  • inclusion in other protocols
Sexes Eligible for Study: All
18 Years to 99 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
GO/URC/ER/mm 64/DG
Not Provided
Not Provided
Not Provided
Giovanni Landoni, Università Vita-Salute San Raffaele
Università Vita-Salute San Raffaele
Not Provided
Not Provided
Università Vita-Salute San Raffaele
October 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP